CoChat

Patient initiation and maintenance of GLP-1 RAs for treatment of obesity

Open access
Patel, Dhiren, Smith, April · 2021 · Expert Review of Clinical Pharmacology

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.

Abstract

Introduction: Healthcare providers (HCPs) see many patients with obesity-related complications and are therefore well placed to help treat obesity itself. However, limited collated information exists to help HCPs with the practical use of anti-obesity medications (AOMs). We focus on the initiation and maintenance of a glucagon-like peptide-1 receptor agonist (GLP-1 RA) for weight management, liraglutide 3.0 mg. Literature search was conducted between 25–28 November 2019 on PubMed and ClinicalTrials.gov.Areas covered: Clinical trial and real-world data describing weight-loss efficacy, cardiometabolic risk factors, incidence of adverse events (AEs), and persistence are presented to assist HCPs with patient discussions. Practical considerations to overcome barriers to optimal use are provided, equipping HCPs with the information required to aid with adherence to and persistence with AOMs. The use of other GLP-1- RA therapies in obesity is discussed in light of the recent US Food and Drug Administration approval of semaglutide 2.4 mg for weight management.Expert opinion: Liraglutide 3.0 mg provides benefits regarding weight loss and improvements in cardiometabolic risk factors. Promising areas of future research in the field of obesity include dual receptor agonists and the combination of glucagon-like peptide-1 receptor agonists with other molecules.

Overview

Integrity signals

Registry

Crossref · 10.1080/17512433.2021.1947796

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 71 references

Research works printed but not linked: 6

  1. Garvey WT, 2016, Endocr Pract, 22, 31
  2. Kolb R, 2016, Curr Opin Pharmacol, 2977
  3. American Medical Association. 2012 Resolutions 2012. [cited 2021 Jun 30]. Available from: https://www.ama-assn.org/sites/ama-assn.org/files/corp/media-browser/public/hod/a12-resolutions_0.pdf
  4. Rondanelli M, 2016, Patient Prefer Adherence, 10407
  5. **Gorgojo-Martinez JJ, Int J Clin Pract, 73, e13399
  6. Ganguly R, 2018, Diabetes Res Clin Pract, 143348

Cited by

See all 21

Metadata

Authors
Patel, D., & Smith, A.
Affiliations
  • Massachusetts College of Pharmacy and Health Sciences (US)
  • Creighton University (US)
Corresponding author
Patel, Dhiren
Venue
Expert Review of Clinical Pharmacology
Published
2021-07-07
Volume
14
Issue
10
Pages
1193-1204
ISSN
  • 1751-2433 (ISSN-L)
  • 1751-2441
OpenAlex
W3182442740
Cited by
16
References
71
Citations by year
2025: 4 · 2024: 2 · 2023: 5 · 2022: 5
FWCI
0.38
Type
journal article
Language
en
Open access
Locations
  • Expert Review of Clinical Pharmacology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Novo Nordisk Inc
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
obesity, GLP-1 receptor agonists, anti-obesity drugs, weight management, weight loss efficacy, cardiometabolic risk factors, adverse events, treatment persistence, medication adherence, dual receptor agonist, combination therapy
MeSH terms
Glucagon-Like Peptide-1 Receptor, Liraglutide, Cardiometabolic Risk Factors, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Animals, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patient initiation and maintenance of GLP-1 RAs for treatment of obesity. https://app.cochat.ai/papers/10.1080/17512433.2021.1947796
The paper
Patel, D., & Smith, A. (2021). Patient initiation and maintenance of GLP-1 RAs for treatment of obesity. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2021.1947796

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.